WP
NRSN icon

Woodline Partners’s NeuroSense Therapeutics NRSN Stock Holding History

Woodline Partners’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,581
Closed -$35.6K – 634
2024
Q1 		$35.6K Buy
+19,581
New +$26.4K ﹤0.01% 528

Other funds holding NRSN

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Woodline Partners's NRSN Position: Q2 2024 in Review

Woodline Partners sold out of NeuroSense Therapeutics (NRSN) in Q2 2024, closing a stake of 19,581 shares — an estimated $35.6K sold.

Woodline Partners first reported a position in NRSN in Q1 2024 and held it in 1 quarter. The position peaked at $35.6K in Q1 2024. 7 funds tracked by Wall St. Rank hold NRSN as of Q2 2024.

  • Woodline Partners reported no remaining NeuroSense Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Woodline Partners sold 19,581 NeuroSense Therapeutics shares in Q2 2024, an estimated $35.6K.
  • Woodline Partners first reported a position in NeuroSense Therapeutics in Q1 2024 and held it in 1 quarter.
  • Woodline Partners's NeuroSense Therapeutics position peaked at $35.6K in Q1 2024.
  • 7 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2024.

Based on Woodline Partners's 13F filing for Q2 2024, filed 14 Aug 2024.